NCT04589845 2026-03-06
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Hoffmann-La Roche
Phase 2 Recruiting
Clinical Trials
14 trialsNCT07415031 2026-02-17
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
Mirati Therapeutics Inc.
Phase 2 Not yet recruiting
NCT05419375 2026-02-03
Screening Study for Participants With Malignant Tumors
Hoffmann-La Roche
Phase 2 Completed
NCT07032077 2025-11-20
A Phase II Clinical Trial on the Safety, Tolerability, and Efficacy of HRS-7058 Combined Anti-tumor Drugs in Subjects With Solid Tumors.
Shandong Suncadia Medicine Co., Ltd.
Phase 2 Recruiting
NCT01197885 2025-06-13
Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer
Astellas Pharma Inc
Phase 2 Completed
NCT04123366 2025-03-17
MK-7339-007
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT03477175 2025-01-07
Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials
Eisai Inc.
Phase 2 Completed
NCT06331598 2024-12-24
IMperator
Hoffmann-La Roche
Phase 2 Withdrawn
NCT03616834 2023-03-22
Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy
Effector Therapeutics
Phase 2 Completed
NCT03264066 2021-05-11
A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors
Hoffmann-La Roche
Phase 2 Completed
NCT02451007 2019-11-19
Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors
PharmaMar
Phase 2 Completed
NCT01634555 2019-02-26
A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI
Eli Lilly and Company
Phase 2 Completed
NCT01624467 2016-07-25
A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors
Eli Lilly and Company
Phase 2 Completed
NCT01940601 2015-01-14
Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim in Pediatric Patients With Solid Tumors
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Withdrawn